Antibodies & Antibody Drug Conjugates

SMi Group9 - 10 April 2018, London, UK.
SMi is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference, being held at the Copthorne Tara Hotel, London, UK. With an every-growing industry, the market is expected to reach USD 30 Billion by 2023. Antibodies and antibody drug conjugates (ADCs) have the potential to make a ground-breaking impact upon medicinal therapies, diagnostics and characterization of diseases. There is massive potential for ADCs to be used in the development of targeted solid tumour therapies, due to their ability to act as precisely and effectively on target antigens.

Join us this April 2018, as SMi’s ADC Summit conference brings together industry experts from leading life science and pharmaceutical companies. Key topics that will be covered in the upcoming event include: fragment drug conjugates, ADC payloads, site-selective ADCs/ site-specific conjugation and the best linker and warhead combinations.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2018:

  • Mahendra Deonarain, Chief Executive and Scientific Officer, Antikor Biopharma
  • Rakesh Dixit, Vice President and Global Head Biologics Safety Assessment, Medimmune

Key Speakers Include:

  • Robert Lyon, Senior Director, Seattle Genetics
  • Arnaud Tiberghien, Scientist II, Spirogen
  • Alison Betts, Associate Research Fellow, Pfizer
  • Thomas Pillow, Senior Scientist, Genentech
  • Andreas Pahl, CSO, Heidelberg Pharma
  • Carlo Boutton, Director of Technology, Ablynx

Some Featured Highlights will include:

  • Learn about the implementation of superior technologies to develop more effective and efficient Antibody Drug Conjugates.
  • Discover new and novel payloads, e.g. Antibody Targeted Amanitin Conjugates (ATACs) and minorgroove binding DNA-interactive molecules as ADC payloads, to expand the ADC landscape.
  • Discuss the practicalities of the use of Highly Potent Active Pharmaceutical Ingredients.
  • Refine the practice of using fragment conjugates in order to develop a tailored therapy for solid tumours.
  • Design principles for maximising the drug delivery efficiency and therapeutic index.

View the full agenda online.

Early-Bird Rates

Book by 15th December and save £400
Book by 31st January and save £200
Book by 28th February and save £100

For further information and to register, please visit:
http://www.adcsummit.com

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...